Drug Type Biosimilar, Monoclonal antibody |
Synonyms NeuLara, Ustekinumab biosimilar |
Target |
Action inhibitors |
Mechanism IL-12p40 inhibitors(Interleukin-12 subunit beta inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |


| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Plaque psoriasis | Phase 1 | Australia | 15 Oct 2019 | |
| Autoimmune Diseases | Phase 1 | - | - |






